Enhancement of ABCA1 and ABCG1 Expression and Cholesterol Efflux by a Metabolite of Tipelukast - A Potential Therapeutic Strategy for Atherosclerosis

Sep 30, 2026

The study tests whether the tipelukast metabolite MN-002, and its parent compound MN-001, enhance macrophage cholesterol efflux through the transporters ABCA1 and ABCG1 to reduce foam cell formation. Cholesterol efflux is measured in THP-1 macrophages and in diabetes patients before and after MN-001 dosing. MN-002 increases ABCA1-mediated efflux and ABCA1/ABCG1 expression independently of PKA, while neither compound improves HDL-mediated efflux. Docking suggests PPAR-alpha binding as a plausible mechanism.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages23

Reading Time58 min

AccessFree to download

Introduction

Residual ASCVD risk beyond LDL-C reduction

Macrophage cholesterol efflux and foam cell prevention

Regulation by ABCA1/ABCG1 and nuclear receptors

Methods

Cellular efflux assays in THP-1 macrophages

ABCA1 and ABCG1 expression analysis

12-week observational study in diabetes patients

Molecular docking for MN-002 targets

Results

Effects of MN-001 and MN-002 on efflux pathways

Effects on transporter expression

Clinical efflux outcome after MN-001

Docking-based target prediction

Conclusion

The official journal of the Japan Atherosclerosis Society and the Asian Pacific Society of Atherosclerosis and Vascular Diseases Original Article J Atheroscler Thromb, 2026; 33: 55-77. [http://doi.org/10.5551/jat.65669](http://doi.org/10.5551/jat.65669) Enhancement of ABCA1 and ABCG1 Expression and Cholesterol Efflux by a Metabolite of Tipelukast: A Potential Therapeutic Strategy for Atherosclerosis Huicheng Qi 1 , 2 , Masatsune Ogura 2 , Kazuko Matsuda 1 and Takashi Miida 2 1 MediciNova,Inc, La Jolla,California, USA 2 Department of Clinical Laboratory Technology, Faculty of Medical Science, Juntendo University, Chiba, Japan Aims: MN-001 (tipelukast), a compound with lipid-modulating and anti-inflammatory properties, and its active metabolite MN-002, have been suggested to influence cholesterol metabolism. This study aimed to investigate whether MN-001 and MN-002 enhance cholesterol efflux via ABCA1 and ABCG1, thereby reducing foam cell formation. We also evaluated cholesterol efflux capacity in patients with diabetes before and after MN-001 administration. Methods: Cholesterol efflux was assessed in THP-1 macrophages treated with MN-001 and MN-002 in the presence of ApoA-I or HDL. ABCA1 and ABCG1 expression were evaluated using western blot and qPCR analyses. A 12-week observational study in patients with diabetes evaluated the cholesterol efflux capacity using ApoB-depleted serum and radiolabeled J774.1 macrophages. Molecular docking simulations were conducted to explore MN-002 binding affinities, aiming to identify potential target proteins and elucidate the molecular mechanisms underlying their effects on cholesterol metabolism. Results: MN-002 enhanced ABCA1-mediated cholesterol efflux and upregulated ABCA1 expression independently of PKA. It also increased ABCG1 expression; however, neither MN-001 nor MN-002 influenced HDL-mediated efflux. MN-001 showed no significant improvement in cholesterol efflux capacity (p = 0.6507) inpatients with diabetes. Molecular docking simulations indicated that MN-002 may bind to PPAR-alpha, suggesting a potential mechanism for its effects. Conclusion: MN-002 offers a novel therapeutic approach for atherosclerosis by upregulating ABCA1 and ABCG1 expression and enhancing ApoA-I-mediated cholesterol efflux. Further studies are required to clarify the underlying mechanisms and assess their clinical potential in atherosclerosis and metabolic disorders. See editorial vol. 33: 26-28 Key words: Tipelukast, Macrophages, ABCA1, Cholesterol efflux, Atherosclerosis | Introduction
Atherosclerotic cardiovascular diseases (ASCVD) remain a leading cause of mortality in developed countries, primarily driven by dyslipidemia and chronic inflammation 1-3) . Low-density lipoprotein cholesterol (LDL-C) is a well-established major risk factor for ASCVD, and LDL-C-lowering therapies, such as statins, have significantly reduced the incidence and mortality associated with ASCVD 1, 2) . | However, even with optimal LDL-C reduction, a substantial residual risk persists. This residual risk is driven by factors such as elevated triglycerides (TG), low high-density lipoprotein cholesterol (HDL-C) levels, and chronic inflammation, which contribute to the progression of atherosclerosis 4-6) .
Addressing this residual risk requires therapeutic strategies beyond lowering the LDL-C levels. Targeting the alternative pathways involved in lipid metabolism and inflammation is essential for | | --- | --- | Address for correspondence: Huicheng Qi, MediciNova, Inc., 4275 Executive Square, Suite 300, La Jolla, California 92037, USA E-mail: [sai@medicinova.com](sai@medicinova.com) [Received: January 30](Received: January 30) , 2025 Accepted for publication: June 11, 2025 Copyright©2026 Japan Atherosclerosis Society This article is distributed under the terms of the latest version of CC BY-NC-SA defined by the Creative Commons Attribution License. advancing ASCVD management 7, 8) . Therapie

FAQs

What was the main aim of the study on MN-001 and MN-002?

To determine whether MN-001 and its active metabolite MN-002 enhance cholesterol efflux via ABCA1 and ABCG1, thereby reducing foam cell formation, and to assess cholesterol efflux capacity in diabetes patients before and after MN-001 administration.

How did MN-002 affect ABCA1- and ABCG1-mediated cholesterol efflux?

MN-002 enhanced ABCA1-mediated cholesterol efflux, upregulated ABCA1 expression independently of PKA, and increased ABCG1 expression. It did not influence HDL-mediated efflux.

What mechanism did molecular docking suggest for MN-002?

Molecular docking simulations indicated that MN-002 may bind to PPAR-alpha, supporting a potential mechanism for its effects on cholesterol metabolism.

Sep 30, 2026

Uploaded by Valentina